Akero Therapeutics Stock Market Value
AKRO Stock | USD 32.17 1.01 3.24% |
Symbol | Akero |
Akero Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Akero Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Akero Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Akero Therapeutics.
06/01/2024 |
| 11/28/2024 |
If you would invest 0.00 in Akero Therapeutics on June 1, 2024 and sell it all today you would earn a total of 0.00 from holding Akero Therapeutics or generate 0.0% return on investment in Akero Therapeutics over 180 days. Akero Therapeutics is related to or competes with Terns Pharmaceuticals, Madrigal Pharmaceuticals, Inozyme Pharma, Viking Therapeutics, Revolution Medicines, Avidity Biosciences, and Protagonist Therapeutics. Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis company, engages in the development of medicin... More
Akero Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Akero Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Akero Therapeutics upside and downside potential and time the market with a certain degree of confidence.
Downside Deviation | 3.01 | |||
Information Ratio | 0.0732 | |||
Maximum Drawdown | 13.37 | |||
Value At Risk | (4.45) | |||
Potential Upside | 5.23 |
Akero Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Akero Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Akero Therapeutics' standard deviation. In reality, there are many statistical measures that can use Akero Therapeutics historical prices to predict the future Akero Therapeutics' volatility.Risk Adjusted Performance | 0.0948 | |||
Jensen Alpha | 0.1306 | |||
Total Risk Alpha | (0.12) | |||
Sortino Ratio | 0.0749 | |||
Treynor Ratio | 0.187 |
Akero Therapeutics Backtested Returns
Akero Therapeutics appears to be very steady, given 3 months investment horizon. Akero Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0993, which signifies that the company had a 0.0993% return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Akero Therapeutics, which you can use to evaluate the volatility of the firm. Please makes use of Akero Therapeutics' risk adjusted performance of 0.0948, and Mean Deviation of 2.37 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Akero Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 1.82, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Akero Therapeutics will likely underperform. Please check Akero Therapeutics' standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Akero Therapeutics' price patterns will revert.
Auto-correlation | 0.47 |
Average predictability
Akero Therapeutics has average predictability. Overlapping area represents the amount of predictability between Akero Therapeutics time series from 1st of June 2024 to 30th of August 2024 and 30th of August 2024 to 28th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Akero Therapeutics price movement. The serial correlation of 0.47 indicates that about 47.0% of current Akero Therapeutics price fluctuation can be explain by its past prices.
Correlation Coefficient | 0.47 | |
Spearman Rank Test | 0.6 | |
Residual Average | 0.0 | |
Price Variance | 5.46 |
Akero Therapeutics lagged returns against current returns
Autocorrelation, which is Akero Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Akero Therapeutics' stock expected returns. We can calculate the autocorrelation of Akero Therapeutics returns to help us make a trade decision. For example, suppose you find that Akero Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
Timeline |
Akero Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Akero Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Akero Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Akero Therapeutics stock over time.
Current vs Lagged Prices |
Timeline |
Akero Therapeutics Lagged Returns
When evaluating Akero Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Akero Therapeutics stock have on its future price. Akero Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Akero Therapeutics autocorrelation shows the relationship between Akero Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Akero Therapeutics.
Regressed Prices |
Timeline |
Pair Trading with Akero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Akero Stock
0.76 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Akero Stock
0.8 | FDMT | 4D Molecular Therapeutics | PairCorr |
0.77 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
0.76 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.66 | PEPG | PepGen | PairCorr |
The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Akero Therapeutics Correlation, Akero Therapeutics Volatility and Akero Therapeutics Alpha and Beta module to complement your research on Akero Therapeutics. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Akero Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.